Two Cases of Primary Malignant Melanoma Treated by Selective Melanoma Thermal Neutron Capture Therapy

  • Kazumi Watanabe
  • Kaoru Ito
  • Yasuyuki Kaneko
  • Sumiko Satake
  • Satoshi Yamada
  • Hideo Yamaguchi
  • Tastuya Takenouchi
  • Masaaki Ito
  • Yutaka Mishima

Abstract

In 1972, the study of Selective Melanoma Thermal Neutron Capture Therapy (Selective-Melanoma NCT) was initiated by Mishima’s group1). In order to apply the theory that reaction products between 10B and neutrons can destroy cells containing 10B 2), 10B had to be transported into malignant melanoma (Mm) cells. For that purpose, 10B1-para-borono-phenylalanine (10B1-BPA) was synthesized. It is a precursor dopa analogue and accumulates in melanosomes within Mm cells (Fig 1) 3,4). 10B1-BPA was complexed with fructose so that it could be soluble at pH near 7.4 (almost equal to blood pH) and be suitable for Selective-Melanoma NCT 5). The first clinical application to metastatic Mm was performed successfully in 1987 1, 6–8). Since then 16 cases of Mm have been treated. Here we report a case of lentigo maligna melanoma on the right face and a case of acral lentiginous melanoma on the right sole, treated by Selective-Melanoma NCT.

Keywords

Inductively Couple Plasma Atomic Emission Spectrometry Thermal Neutron Primary Malignant Melanoma Boron Neutron Capture Therapy Lithium Atom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. I. Y. Mishima, C. Honda, M. Ichihashi, II. Obata, J. Hiratsuka, H. Fukuda, H. Karashima, T. Kobayashi, K. Kanda and K. Yoshino, Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound, Lancet 11, 388–389, 1989.CrossRefGoogle Scholar
  2. 2.
    W. Entzian, A.H. Soloway, R. Raju, W.H. Sweet, G.L. Brownell, Effect of neutron capture irradiation upon malignant brain tumors in mice, Acta Radio], 5: 95–100, 1966.CrossRefGoogle Scholar
  3. 3.
    K. Yoshino, M. Kotaka, H. Kakihana, 11B-BMR study of the complex formation of borate with catechol and L-dopa, Bull of Chem Soc Japan 52: 3005–3009, 1979.CrossRefGoogle Scholar
  4. 4.
    M. Ichihashi, T. Nakanishi, Y. Mishima, Specific killing effect of 10131-para-boronophenylalanine in thermal neutron capture therapy of malignant melanoma: in vino radiobiological evaluation, J Invest Dermatol, 78: 215–218, 1982.PubMedCrossRefGoogle Scholar
  5. 5.
    K. Yoshino, A. Suzuki, Y. Mori, H. Kakihana, C. Honda, Y. Mishima, T. Kobayashi, K. Kanda, Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides, Strahlenther Onkol, 165: 127–129, 1989.PubMedGoogle Scholar
  6. 6.
    Y. Mishima, C. Honda, M. Ichihashi, S. Hatta, C. Honda, K. Yamamura. T. Nakagawa, New thermal capture therapy for malignant melanoma: melanogenesis-seeking 10B molecule-melanoma cell interaction from in vitro to first clinical trial, Pig Cell Res, 2: 226–234, 1989.CrossRefGoogle Scholar
  7. 7.
    H. Fukuda, T. Kobayashi, J. Hiratsuka, H. Karashima, C. Honda, K. Yamamura, M. Ichihashi, K. Kanda, Y. Mishima, Estimation of absorbed dose in the covering skin of human melanoma treated by neutron capture therapy, Pig Cell Res, 2: 365–369, 1989.CrossRefGoogle Scholar
  8. 8.
    T. Kobayashi, S. Hatta, C. Honda, K. Yamamura, T. Akiyoshi, K. Kanda, Y. Mishima, Estimation of absorbed doses in human malignant melanoma treated by neutron capture therapy with special references to vertical direction, Pig Cell Res, 2: 361–364, 1989.CrossRefGoogle Scholar
  9. 9.
    T. Kobayashi, K. Kanda, Y. Ujeno, H. Fukuda, K. Ando, J. Hiratsuka, Y. Mishima, and M. Ichihashi, Irradiation conditions based on absorbed dose estimation in boron neutron capture therapy for superficially located malignant melanoma, Radiat Biol Res Commun, 25: 53–64. 1990.Google Scholar
  10. 10.
    S. R. Tamat, D.E. Moore, and B.J. Allen, Determination of boron in biological tissues by inductively coupled plasma atomic emission spectrometry, Anal Chem, 59: 2161–2164, 1987.PubMedCrossRefGoogle Scholar
  11. 11.
    K. Yoshino, C. Nishino, E. Ubukata, T. Maruyama, Y. Mori, Y. Mishima, C. Honda, M. Shiono, N. Wadabayashi, M. Ichihashi, T. Kobayashi, and K. Kanda, Rapid spectrophotometric determination of boron in biological tissue with alkali fusion decomposition, in “Progress in Neutron Capture for Cancer”, Plenum Press, New York, 1992, pp. 309–312.CrossRefGoogle Scholar
  12. 12.
    H. Fukuda, J. Hiratsuka, C. Honda, T. Kobayashi, K. Yoshino, H. Karashima, J. Takahashi, Y. Abe, K. Kanda, M. Ichihashi, and Y. Mishima, Boron neutron capture therapy of malignant melanoma using 1°B1-para-boronophenylalanine with special reference to evaluation of radiation dose and damage to the normal skin, Radiat Res, 138: 435–442, 1994.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Kazumi Watanabe
    • 1
  • Kaoru Ito
    • 1
  • Yasuyuki Kaneko
    • 1
  • Sumiko Satake
    • 1
  • Satoshi Yamada
    • 1
  • Hideo Yamaguchi
    • 1
  • Tastuya Takenouchi
    • 1
  • Masaaki Ito
    • 1
  • Yutaka Mishima
    • 2
  1. 1.Department of DermatologyNiigata University School of MedicineNiigataJapan
  2. 2.Mishima Institute for Dermatological ResearchKobeJapan

Personalised recommendations